Target Name: CCNT1
NCBI ID: G904
Review Report on CCNT1 Target / Biomarker Content of Review Report on CCNT1 Target / Biomarker
CCNT1
Other Name(s): CycT1 | Cyclin-T | HIVE1 | CCNT1 variant a | MLLT10/CCNT1 fusion | CCNT1_HUMAN | CCNT | Cyclin C-related protein | human immunodeficiency virus type 1 (HIV-1) expression (elevated) 1 | Cyclin T1, transcript variant a | CYCT1 | Subunit of positive elongation transcription factor b | CDK9-associated C-type protein | Cyclin-T1 | cyclin C-related protein | cyclin T1

Understanding CycT1: Potential Drug Targets for Cancer and Neurodegenerative Diseases

CycT1, also known as CCNT1, is a protein that is expressed in various tissues of the body, including the brain, heart, and gastrointestinal tract. It is a member of the tyrosine kinase family and is involved in the regulation of cell proliferation, differentiation, and survival. The study of CycT1 has important implications for our understanding of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Disease-related functions of CycT1

CycT1 is involved in several disease-related functions, including:

1. Cell proliferation and survival: CycT1 plays a role in the regulation of cell proliferation and has been shown to be involved in the development and progression of cancer. It has been shown to promote the growth and survival of cancer cells, and is often used as a potential drug target in cancer treatment.
2. Neurodegenerative diseases: CycT1 has been shown to be involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. It has been shown to promote the formation of neurofibrillary tangles and invasions in the brain, which are hallmarks of these diseases.
3. Autoimmune disorders: CycT1 has been implicated in the development and maintenance of autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. It has been shown to regulate the immune response and contribute to the development of autoimmune diseases.

Cancer-related functions of CycT1

CycT1 is involved in the regulation of cell proliferation and has been shown to contribute to the development and progression of cancer. It has been shown to promote the growth and survival of cancer cells and can be used as a potential drug target in cancer treatment.

Cytotoxic effects of CycT1

CycT1 has been shown to have cytotoxic effects on a variety of cell types, including cancer cells, normal cells, and immune cells. It has been shown to induce cell death, either through apoptosis or necroptosis.

Drug targeting of CycT1

Drug targeting of CycT1 is a promising approach to the treatment of various diseases. One potential approach is to use small molecules or antibodies to inhibit the activity of CycT1. Small molecules, such as inhibitors of tyrosine kinase signaling pathways, have been shown to inhibit the activity of CycT1 and prevent its growth and survival. Antibodies have also been shown to target CycT1 and prevent it from interacting with its downstream targets.

Conclusion

CycT1 is a protein that is involved in the regulation of cell proliferation and has been implicated in the development and progression of various diseases. Its role in these processes makes it an attractive target for drug development in the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand the functions of CycT1 and to develop effective treatments based on its properties.

Protein Name: Cyclin T1

Functions: Regulatory subunit of the cyclin-dependent kinase pair (CDK9/cyclin-T1) complex, also called positive transcription elongation factor B (P-TEFb), which facilitates the transition from abortive to productive elongation by phosphorylating the CTD (C-terminal domain) of the large subunit of RNA polymerase II (RNA Pol II) (PubMed:16109376, PubMed:16109377, PubMed:35393539, PubMed:30134174). Required to activate the protein kinase activity of CDK9: acts by mediating formation of liquid-liquid phase separation (LLPS) that enhances binding of P-TEFb to the CTD of RNA Pol II (PubMed:29849146, PubMed:35393539)

The "CCNT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCNT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CCNT2 | CCNT2-AS1 | CCNT2P1 | CCNY | CCNYL1 | CCNYL2 | CCP110 | CCPG1 | CCR1 | CCR10 | CCR12P | CCR2 | CCR3 | CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2 | CCS | CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1 | CCZ1B | CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G